In this Exclusive Interview, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about diabetes drugs in the pipeline at Merck; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and the problem of “clinical inertia” in intensifying treatment.
Diabetes in Control speaks with top endocrinologists and other medical professionals to bring you the latest in diabetes news and research.
Dr. Sam Engel is the Associate Vice President, Cardiometabolic and Women’s Health at Merck Research Laboratories. He graduated from New York University School of Medicine. Prior to joining Merck’s team, he was a Clinical Professor at Albert Einstein College of Medicine.
Pt.1: CompoSIT-I Study
Pt.2: CompoSIT-R Study
Pt.3: Merck Diabetes Drugs Future and Present
Pt.4: The Ramifications of Clinical Inertia
Pt.5: CGM Effect on Diabetes